SUPPLIER AUDITING PROGRAMS
This article was originally published in The Gold Sheet
Executive Summary
...are being developed covering excipient manufacturers and computer vendors as part of a pharmaceutical industry push to broaden quality assurance. Suppliers and users are cooperating on the two auditing programs designed to standardize auditing practices and reduce the overall resource burden. To complement its new auditing program, the International Pharmaceutical Excipients Council is developing a series of excipient guides based on its GMP document that will address -- auditing manufacturers and distributors -- handling manufacturing changes -- profiling impurities n n formulating certificates of analysis -- and developing specifications. The association PDA is launching a "shared" auditing program for computer suppliers similar to the IPEC effort. A new guide on cooperative manufacturing arrangements from CBER will expand the use of contract manufacturing and create new communication and auditing challenges for participating biologics companies. [A discussion by a DuPont official of the firm’s auditing program for foreign contract manufacturers begins on p. 15.]
You may also be interested in...
Threat of Sanctions, Shortages, Spurs Talk of Standards for Atypical Actives
As the pharmaceutical supply chain comes under increased regulatory scrutiny, FDA inspectors are finding manufacturers using excipients as active ingredients, even though they don’t meet active ingredient standards, and the industry is talking about establishing a new set of standards for these so-called atypical actives, and perhaps coaxing FDA into ratifying them via guidance.
McKinsey Survey Highlights Progress, Challenges in Adoption of QbD
Drug manufacturers are adopting QbD but there are exceptions, especially among some generics firms, McKinsey finds in industry survey. The top challenge to further adoption: misalignment between R&D and commercial operations. Second is a lack of belief in the business case. However, the cost turns out to be low and the financial reward high, McKinsey says.